P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.Peer-Reviewed Original ResearchIntravenous immunoglobulinMyasthenia gravisAnti-acetylcholine receptor antibody-positive refractoryRefractory myasthenia gravisOpen-label extensionPlacebo-controlled studyMeaningful clinical improvementExperienced exacerbationRescue therapyClinical improvementEighteen patientsMore patientsSubgroup analysisEculizumabPatientsPlaceboExacerbationRelevant improvementGravisPhase 3Status changesInterim dataImmunoglobulinPrevious reportsMeaningful responses